Trial Profile
A Phase II Study of Sunitinib in Patients With Refractory or Relapsed Germ Cell Tumors.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 10 Nov 2021
Price :
$35
*
At a glance
- Drugs Sunitinib (Primary)
- Indications Germ cell cancer
- Focus Therapeutic Use
- 26 May 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 10 Jan 2009 Status changed from recruiting to active, no longer recruiting, according to ClinicalTrials.gov.
- 12 Apr 2007 Status changed from initiated